Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume -, Issue -, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/bjd/ljad324
Keywords
-
Categories
Ask authors/readers for more resources
The use of dupilumab in the treatment of ICI-induced bullous pemphigoid is suggested, but caution is advised regarding the targeted inhibition of the Th2 pathway due to evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, on ICI responses, especially in melanoma.
The use of dupilumab has been suggested in the treatment of immune checkpoint inhibitor (ICI)-induced bullous pemphigoid. In this letter, we express caution with the targeted inhibition of the Th2 pathway given current evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, to ICI responses, particularly in melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available